InvestSMART

Medical Developments International Limited (ASX:MVP)

ALERT: Price-sensitive ASX Announcement for MVP
Current share price for MVP : $0.395 -0.12 (-23.30%)+
Announcement
Release
20 Aug 2026 8:56AM
Price at Release
$0.515
Full Release
download
Summary
Medical Developments International Limited reported a solid financial performance for FY26, with a 9% increase in group revenue to $42.6 million. The major highlight was the growth in the Pain Management segment, with revenue up by 21% due to higher volumes across all regions and increased pricing in Australia. Penthrox®, their flagship product, saw significant volume growth, especially in Europe and the Australian hospital segment, contributing to the expansion of its addressable market to children aged 6 and above in Europe. Although Respiratory segment revenue decreased by 15% due to softer demand, the company improved its free cash flow by $5.8 million. This performance was supported by strong overhead cost control and strategic initiatives such as the transition to a capital light operating model in France and Switzerland, alongside continued efforts to enhance operational efficiencies.
Key Points
  • FY26 saw a 9% increase in group revenue to $42.6 million.
  • Pain Management segment revenue increased by 21%.
  • Penthrox® volume grew significantly in Europe and Australia.
  • Penthrox® market expanded to include children aged 6+ in Europe.
  • Respiratory segment revenue decreased by 15%.
  • Free cash flow improved by $5.8 million.
  • Strong overhead cost control was maintained.
  • Transitioned to a capital light model in France and Switzerland.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.